Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 

 

Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Jan 27, 2023

Dr. Jula Inrig is the Chief Medical Officer of Travere Therapeutics and is eager to find innovative treatments for rare kidney diseases, which can be challenging to diagnose and have limited therapeutic options. In clinical trials, their lead candidate, sparsentan, reduces proteinuria significantly in patients with IgA Nephropathy and focal segmental glomerulosclerosis (FSGS). Travere is working with the U.S. Preventive Task Force to encourage earlier diagnosis and screening for these often silent diseases.

Jula explains, "We've mapped out a path to get therapies approved for trying to avoid really what is one of the most detrimental complications of kidney disease, which is kidney failure, where you essentially wind up on dialysis. This is a treatment option where patients need to go into a clinic and be hooked up to a machine which cleans their blood three times a week. Or the other option is transplantation. One of the things that we have worked on is a molecule called sparsentan to try and avoid kidney failure."

"Sparsentan is an investigational product candidate. It is a single molecule that doesn't suppress the immune system, which I think for a lot of our patients that's very important. It blocks two hormones that are in the path of causing damage within the kidney. What we have found with sparsentan is it reduces the pressure within the kidney, and it causes some remodeling within the kidney that reduces leakage of protein. When you leak protein within your kidney, that causes the kidney to then not clear toxins and then ultimately to progress faster causing kidney failure."

@TravereRare #TravereTherapeutics #RareDiseases #RareKidneyDisease #KidneyDisease #EarlyDiagnosis

Travere.com

Listen to the podcast here